HIV Infections Clinical Trial
— IWPrEPOfficial title:
Leveraging the Emergency Department to Engage African American Women in HIV Pre-Exposure Prophylaxis
Verified date | August 2022 |
Source | The University of Texas Health Science Center, Houston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
African American (AA) women are more vulnerable to HIV infection than other women. Truvada, when used as pre-exposure prophylaxis (PrEP), is one of the most effective approaches for HIV prevention; however, PrEP use among AA women remains low and has not responded to traditional interventions. This study proposes for the first time an innovative computer-based motivational intervention, increasing PrEP uptake (iPrEP), which couples motivational messages woven into a traditional survey to raise awareness of risky sex and substance use behaviors.
Status | Completed |
Enrollment | 40 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Current HIV negative status (based on ED' HIV test outcome) - Condomless sex in the last 3 months - Substance use in the last 3 months - HIV testing during ED visit (usual care) - Has a non-emergent health condition - Has a working mobile device with them Exclusion Criteria: - Ineligible for PrEP (see eligibility criteria to the right) - Assigned male at birth - An HIV positive status - Currently taking medication that are known contraindications for PrEP (brand name: Truvada) - Currently on PrEP |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Health Science Center at Houston | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with an increased willingness for pre-exposure prophylaxis (PrEP) uptake | Participants will be assessed for social norms and risk. | 1 month | |
Primary | Number of participants with an increased willingness for pre-exposure prophylaxis (PrEP) uptake | Participants will be assessed for social norms and risk. | 3 months | |
Primary | Number of participants with an increased willingness for pre-exposure prophylaxis (PrEP) uptake | Participants will be assessed for social norms and risk. | 6 months | |
Secondary | Number of participants with decreased high risk sex | 1 month | ||
Secondary | Number of participants with decreased high risk sex | 3 months | ||
Secondary | Number of participants with decreased high risk sex | 6 months | ||
Secondary | Number of participants with decrease in substance use | 1 month | ||
Secondary | Number of participants with decrease in substance use | 3 months | ||
Secondary | Number of participants with decrease in substance use | 6 months | ||
Secondary | Number of participants with a new sexually transmitted disease diagnosis | 1 month | ||
Secondary | Number of participants with a new sexually transmitted disease diagnosis | 3 months | ||
Secondary | Number of participants with a new sexually transmitted disease diagnosis | 6 months | ||
Secondary | Number of participants with HIV seroconversion | 1 month | ||
Secondary | Number of participants with HIV seroconversion | 3 months | ||
Secondary | Number of participants with HIV seroconversion | 6 months | ||
Secondary | iPrEP feasibility and acceptability as assessed by the number of participants who believe that they had more information to make a better decision about being in a PrEP program after completing the survey intervention | As part of the survey, participants will be asked if they believe that they had more information to make a better decision about being in a PrEP program after completing the survey intervention. | baseline | |
Secondary | iPrEP feasibility and acceptability as assessed by how much participant liked or disliked completing the survey | As part of the survey, participants will asked "How much did you like or dislike completing this questionnaire?" and will choose one of the following 5 categorical choices: Liked it, Liked it somewhat, Neither liked nor disliked it, Disliked it somewhat, Disliked it | baseline | |
Secondary | iPrEP feasibility and acceptability as assessed by how often participants relied on the survey questions being read aloud to be able to answer them | As part of the survey, participants will asked "As you completed this questionnaire, how often did you rely on the questions being read aloud to be able to answer them?" and will choose one of the following 4 categorical choices: For all the questions, For most of the questions, For some of the questions, For none of the questions | baseline | |
Secondary | iPrEP feasibility and acceptability as assessed by number of participants who needed help from site staff in order to complete the survey | As part of the survey, participants will be asked if they needed help from site staff in order to complete the survey. | baseline | |
Secondary | iPrEP feasibility and acceptability as assessed by the kind of help that participants needed from site staff in order to complete the survey | As part of the survey, participants will asked "What kind of help did you need? Please check all that apply" and will choose among the following categorical 4 choices: I had to have some of the questions explained to me, I needed help using the iPAD, I needed to have the questionnaire read to me by a staff member, I needed help for a different reason | baseline | |
Secondary | iPrEP feasibility and acceptability as assessed by how participants felt about the length of the survey | As part of the survey, participants will asked how they felt about the length of the survey and will choose one of the following 3 categorical choices: Too long, Too short, The right length | baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |